{"ticker": {"uuid": "0c54612b-f633-4012-911f-3730046fe03b", "symbol": "XSPRAY", "name": "Xspray Pharma AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "FDA puts the brakes on Xspray Pharma's Nilopki approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNYUtqcVpOMmFUMGVZYmEyd2k1SVpMa2w3UGp5a0ZzTDI5LWVjQ194WmZUNE1zTnJnLWprMjg5SGh6UW1GMWs2Q2hYMnh1OUZQTlJ2SlR0R2pWb3lhOXEyS0pNWVhiaWhmM2hDckNqRDR6YjdGTkFvWjFmTENUR3RpSEVYN1RJM1EzaFE?oc=5", "source_name": "Biostock", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray\u2019s rights issue oversubscribed \u2013 over-allotment issue fully utilized", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSkRrY2VfeXBGUEE4QTNPQ0hwU3AwN19oUy1YbWZ2QTNUbi0yajNVZi1CTExLc2V4RHptYVNmRVUtNVdDc1lTckVCU1lqLXRXS1RHWEM2aHljR19XSXdLeEI3QWdUZ0s3WFlxREtwNXozbjZsUzJOeXVrYWRMWkV0Q0R4VDlEbGx4b1ZUYWtRWndVVkhlWFJSZ1lnUnliRnNNR1NsLWg0YUNkcUF4YXczdmQ3aW5WbDhoUkVaUDdDWjFoa1FQa2czajZISlk1SE1DUmRmbw?oc=5", "source_name": "TradingView", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xspray Pharma (STO:XSPRAY) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA throws cold water on Xspray's latest approval bid with rejection over manufacturing, label concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWGFmQ2lHb0dyQmVnNU5xUDkwQ3hQYlJoVkttOFVfaVd4b3dnVnNLZWZZdXZhYkF3TGZ4ZlhRQlpuYS1Ta2hmb2gzRHotWm4yMUFCZE5maVVIZ3hPWU56N29oLWtpTmxMUWQyZEN0cTV5OGFrOHpmYVM5b0dNNURzcG9RZmNyMndxcUxXbnVwY2wtN2F5a3BqU0RqT0xaN2J3TUVKOFBXdHVxSDd3MzVoS3VzY1NjZFRaOW9YNTU5S01yMmxsd2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray Pharma's CEO: \"XS003 shows that we are building a powerhouse \u2013 Dasynoc is just the beginning\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNV1h6Vy1yMVVnZTdLdHkwWHV6dTA2WENNYV9MQ3ZoeG15VHZ6VjVscG42bkd6TWN5MGl2X0gybWxQckd3Ny1ueTY1Zmx2eW4zdFdEWWI3RmpTQVVrNjhZMTN4aE5keUFuQVo1TkxtUjUxZU5Pc2hhQkgweWxzTWg5T1BWTmRFUDZYTEhZVVJqZ01fRDhtWmJXVHpyUm1SRUhmZ2Y1OXhpM25sVXJZaHViMXVtMA?oc=5", "source_name": "Biostock", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray Pharma CEO: \"Hope to launch end of 2025\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOMjd6VU1vdENFU05qcWUtY3l4a3htZDVMSHdJRWVjdkRYRnd1Vmh3Tl9DM0huRWhvTWJkTE4xS1BQQ2xxUkc2bWNPSFNhTFV2dXlHQXRoM0t5QV8xejgzaGszXzJmUXoyd2VoTXlyWHB3dDN5LWNRU1dFQjRma0JPYWJadExrUQ?oc=5", "source_name": "Biostock", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray backs down after delayed FDA application", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1RR2RQQ2ZWOElnM1RDUkhmcmx6bjFBUzM4U0FyS1NsUGV5ODkxYnRrQWFLYWdRaVVqRE9WeEYyM2o0LWFDLWRjUWlLaXVVcWZUVF9xNWl3amRJWlg0a1Rabk0zV0dvdDBwWmpSU0ZWWVhMUDJxdUI4SHRtc0c?oc=5", "source_name": "Biostock", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XSPRAY Stock Price and Chart \u2014 OMXSTO:XSPRAY", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE8tUjBTdVd3WWx2SnhNVU9GRW9vMGVwXzc3RjRncDg0MGpYQkt0OEVQVnlLNlRKWTlkc1RNenZSbmZkUjh2QTBvSE5BbUdGcVhPZXE1VnJRR1JncVNkUG53?oc=5", "source_name": "TradingView", "published_at": "2018-04-14T02:12:37+00:00", "published_display": "14 Apr 2018 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FDA puts the brakes on Xspray Pharma's Nilopki approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNYUtqcVpOMmFUMGVZYmEyd2k1SVpMa2w3UGp5a0ZzTDI5LWVjQ194WmZUNE1zTnJnLWprMjg5SGh6UW1GMWs2Q2hYMnh1OUZQTlJ2SlR0R2pWb3lhOXEyS0pNWVhiaWhmM2hDckNqRDR6YjdGTkFvWjFmTENUR3RpSEVYN1RJM1EzaFE?oc=5", "source_name": "Biostock", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray\u2019s rights issue oversubscribed \u2013 over-allotment issue fully utilized", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSkRrY2VfeXBGUEE4QTNPQ0hwU3AwN19oUy1YbWZ2QTNUbi0yajNVZi1CTExLc2V4RHptYVNmRVUtNVdDc1lTckVCU1lqLXRXS1RHWEM2aHljR19XSXdLeEI3QWdUZ0s3WFlxREtwNXozbjZsUzJOeXVrYWRMWkV0Q0R4VDlEbGx4b1ZUYWtRWndVVkhlWFJSZ1lnUnliRnNNR1NsLWg0YUNkcUF4YXczdmQ3aW5WbDhoUkVaUDdDWjFoa1FQa2czajZISlk1SE1DUmRmbw?oc=5", "source_name": "TradingView", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xspray Pharma (STO:XSPRAY) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSS1UNzVqX0pRYXp5anV1Tm5EMnlLOHloeXhIbXJCVnlxOXBBNl9mWHpaMW44T0JlMnRrTzFDYTg1d2ZqSkdvZFc1aWIzenBsVFVQUVdLQi1EV1FDdExONVFxSmJUc01MVFNZVmcxZ05ZcTFMNHN6eE5MYmFjSnExVVhCOGxfRnNhV2YxSE0ycU1OTnRibHhjREVpTGZtcllob09mZkJ5bDc3QzQwSkwzQWtaOHdaU3MyVUJiLXdmdXBNYzhPa1k0dmdXWmZObUpvdFlnZU9hQjZ4SDZGb2o0OENUdXVBWmPSAewBQVVfeXFMTzkxUDdGLWs4UVpaSHdxSDUyZDJiUE9STjdwOWdoSTQ1S1lBQUVUandwODhObHRwajVrZHBnM0ZlbXRHUmZQd3dKWXNfdzJtY1MwbWV4MUZrX3U5eGlrOWRYWXV0ZXRVRmh0SG9jbTJDYVUyQVZXLTRtaFppU0hpV1NMVTZuT2dDWFpHR3AzYkVSR25mOW1aZVBlRVhYMWdNUEhsX3NqT2NreWdkbTU0aVVLSHhCR294Q0N6OXhHWnZDci1qVHlHWnd1Y0dGOFZjZVZ0ZTFEZDBpeXVsa0hSUy03U2NoMTFpdGN4Q0U?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA throws cold water on Xspray's latest approval bid with rejection over manufacturing, label concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWGFmQ2lHb0dyQmVnNU5xUDkwQ3hQYlJoVkttOFVfaVd4b3dnVnNLZWZZdXZhYkF3TGZ4ZlhRQlpuYS1Ta2hmb2gzRHotWm4yMUFCZE5maVVIZ3hPWU56N29oLWtpTmxMUWQyZEN0cTV5OGFrOHpmYVM5b0dNNURzcG9RZmNyMndxcUxXbnVwY2wtN2F5a3BqU0RqT0xaN2J3TUVKOFBXdHVxSDd3MzVoS3VzY1NjZFRaOW9YNTU5S01yMmxsd2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray Pharma's CEO: \"XS003 shows that we are building a powerhouse \u2013 Dasynoc is just the beginning\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNV1h6Vy1yMVVnZTdLdHkwWHV6dTA2WENNYV9MQ3ZoeG15VHZ6VjVscG42bkd6TWN5MGl2X0gybWxQckd3Ny1ueTY1Zmx2eW4zdFdEWWI3RmpTQVVrNjhZMTN4aE5keUFuQVo1TkxtUjUxZU5Pc2hhQkgweWxzTWg5T1BWTmRFUDZYTEhZVVJqZ01fRDhtWmJXVHpyUm1SRUhmZ2Y1OXhpM25sVXJZaHViMXVtMA?oc=5", "source_name": "Biostock", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray Pharma CEO: \"Hope to launch end of 2025\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOMjd6VU1vdENFU05qcWUtY3l4a3htZDVMSHdJRWVjdkRYRnd1Vmh3Tl9DM0huRWhvTWJkTE4xS1BQQ2xxUkc2bWNPSFNhTFV2dXlHQXRoM0t5QV8xejgzaGszXzJmUXoyd2VoTXlyWHB3dDN5LWNRU1dFQjRma0JPYWJadExrUQ?oc=5", "source_name": "Biostock", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xspray backs down after delayed FDA application", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1RR2RQQ2ZWOElnM1RDUkhmcmx6bjFBUzM4U0FyS1NsUGV5ODkxYnRrQWFLYWdRaVVqRE9WeEYyM2o0LWFDLWRjUWlLaXVVcWZUVF9xNWl3amRJWlg0a1Rabk0zV0dvdDBwWmpSU0ZWWVhMUDJxdUI4SHRtc0c?oc=5", "source_name": "Biostock", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XSPRAY Stock Price and Chart \u2014 OMXSTO:XSPRAY", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE8tUjBTdVd3WWx2SnhNVU9GRW9vMGVwXzc3RjRncDg0MGpYQkt0OEVQVnlLNlRKWTlkc1RNenZSbmZkUjh2QTBvSE5BbUdGcVhPZXE1VnJRR1JncVNkUG53?oc=5", "source_name": "TradingView", "published_at": "2018-04-14T02:12:37+00:00", "published_display": "14 Apr 2018 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 65, "total_relevant": 8, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 7, "score": 52, "total": 8, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 14.94, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": -1.3, "twelve_week_move": -47.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.249532, "market_dynamics_buy_signal": false, "relative_strength": -57.214971, "fair_value_gap": -62.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.8299, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, -1.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Biostock", "count": 4}, {"label": "TradingView", "count": 2}, {"label": "simplywall.st", "count": 1}, {"label": "Fierce Pharma", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 8}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "8", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.6% over one week, -1.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "FDA puts the brakes on Xspray Pharma's Nilopki approval"}], "updated_at": "2026-07-18T00:09:31.582072+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}